Lab
Ethos Holding Corp
Ethos Holding Corp was paid $28.52M by Medicaid between Jan 2018 and Dec 2024, across 127 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 28% of everything it billed.
33Billing provider infoETHOS HOLDING CORP
NEWPORT, KY 41071
NEWPORT, KY 41071
33aNPI1104255215assigned 11/08/2013
33bProvider typeClinical Medical Laboratory
28Total paid$28.52M
24GClaims1,191,286
24DCodes billed127
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Kentucky
Rank by total paid#4 of 73
Median peer was paid$95K
This provider vs. median300×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 205,671 | $3.85M | |
| 2019 | 153,219 | $2.83M | |
| 2020 | 154,826 | $3.05M | |
| 2021 | 274,841 | $7.19M | |
| 2022 | 204,726 | $5.33M | |
| 2023 | 134,769 | $4.01M | |
| 2024incomplete | 63,234 | $2.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 28% | 142,593 | 40,793 | $8.10M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 19% | 86,765 | 72,378 | $5.50M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 9.7% | 138,970 | 120,418 | $2.77M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 7.6% | 62,398 | 52,328 | $2.16M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 6.9% | 118,976 | 35,059 | $1.97M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 5.7% | 36,170 | 28,572 | $1.63M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4.4% | 100,422 | 30,132 | $1.26M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.8% | 32,599 | 27,443 | $794K |
| 0117U | 2.2% | 18,343 | 16,447 | $638K | |
| 83921 | 1.5% | 30,035 | 26,156 | $420K | |
| 82542 | 1.3% | 29,462 | 25,585 | $360K | |
| 83789 | 1.2% | 29,497 | 25,608 | $343K |
115 more codes
| 84207 | 1.1% | 29,872 | $325K | |
| 83918 | <1% | 29,817 | $234K | |
| 83090 | <1% | 29,420 | $196K | |
| 84585 | <1% | 30,066 | $188K | |
| 83497 | <1% | 30,065 | $159K | |
| 80361 | <1% | 7,929 | $64K | |
| 80356 | <1% | 7,548 | $61K | |
| 83992 | <1% | 6,783 | $57K | |
| 80359 | <1% | 7,038 | $54K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,229 | $54K |
| 80353 | <1% | 7,237 | $52K | |
| 80365 | <1% | 7,091 | $52K | |
| 80321 | <1% | 6,932 | $48K | |
| 82570 | <1% | 25,050 | $48K | |
| 80348 | <1% | 7,020 | $46K | |
| 80373 | <1% | 6,611 | $46K | |
| 80354 | <1% | 6,748 | $45K | |
| 80346 | <1% | 5,900 | $44K | |
| 80349 | <1% | 6,354 | $44K | |
| 80372 | <1% | 6,254 | $43K | |
| 80324 | <1% | 4,530 | $40K | |
| 80375 | <1% | 6,246 | $38K | |
| 80342 | <1% | 2,627 | $38K | |
| 80355 | <1% | 4,451 | $38K | |
| 80358 | <1% | 6,030 | $37K | |
| 80364 | <1% | 5,677 | $36K | |
| 80366 | <1% | 3,335 | $30K | |
| 80368 | <1% | 2,931 | $29K | |
| 80320 | <1% | 3,780 | $29K | |
| 80371 | <1% | 3,069 | $26K | |
| 80338 | <1% | 2,945 | $23K | |
| 80336 | <1% | 2,267 | $22K | |
| 80332 | <1% | 1,870 | $21K | |
| 80370 | <1% | 2,220 | $20K | |
| 80360 | <1% | 3,104 | $20K | |
| 80345 | <1% | 2,950 | $20K | |
| 80367 | <1% | 2,682 | $19K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,172 | $18K |
| 80325 | <1% | 2,867 | $18K | |
| 80323 | <1% | 2,120 | $17K | |
| 80363 | <1% | 1,205 | $17K | |
| 80369 | <1% | 1,430 | $16K | |
| 80357 | <1% | 2,331 | $14K | |
| 80333 | <1% | 1,689 | $14K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 172 | $13K |
| 80329 | <1% | 1,314 | $10K | |
| 80347 | <1% | 712 | $10K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 485 | $8K |
| 81226 | <1% | 70 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 324 | $4K |
| 86480 | <1% | 114 | $4K | |
| 86780 | <1% | 356 | $3K | |
| 80074 | <1% | 296 | $3K | |
| 80362 | <1% | 250 | $3K | |
| 87522 | Neg quan hep c or qual rna | <1% | 126 | $3K |
| 86803 | <1% | 210 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 974 | $2K |
| 80322 | <1% | 230 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,512 | $2K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | <1% | 1,421 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 824 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,865 | $2K |
| 86328 | <1% | 107 | $1K | |
| 80335 | <1% | 91 | $1K | |
| 81225 | <1% | 83 | $1K | |
| 80061 | Lipid panel | <1% | 1,002 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,236 | $1K |
| 81227 | <1% | 84 | $935.57 | |
| 84481 | <1% | 698 | $932.98 | |
| 87150 | <1% | 122 | $879.91 | |
| 0011A | <1% | 281 | $858.89 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 246 | $814.08 |
| 82607 | <1% | 748 | $800.97 | |
| 80053 | Comprehensive metabolic panel | <1% | 1,270 | $774.58 |
| 0012A | <1% | 198 | $669.82 | |
| 0013A | <1% | 366 | $620.22 | |
| 87500 | <1% | 88 | $456.69 | |
| 84439 | <1% | 704 | $451.30 | |
| 84460 | <1% | 222 | $429.67 | |
| 84075 | <1% | 223 | $419.60 | |
| 84450 | <1% | 222 | $419.58 | |
| 82247 | <1% | 223 | $404.49 | |
| 80326 | <1% | 60 | $363.31 | |
| 83735 | <1% | 598 | $349.25 | |
| 82040 | <1% | 344 | $300.35 | |
| 84155 | <1% | 248 | $272.77 | |
| 82947 | <1% | 83 | $216.27 | |
| 83690 | <1% | 87 | $164.39 | |
| 87640 | <1% | 61 | $162.68 | |
| 82150 | <1% | 85 | $154.40 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 41 | $153.48 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 41 | $153.48 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 40 | $138.91 |
| 87653 | <1% | 40 | $138.91 | |
| 80374 | <1% | 12 | $85.40 | |
| 82565 | <1% | 302 | $84.54 | |
| 0071A | <1% | 84 | $82.81 | |
| 87400 | <1% | 27 | $69.96 | |
| 80076 | <1% | 15 | $64.90 | |
| 84520 | <1% | 215 | $64.16 | |
| 0064A | <1% | 80 | $62.79 | |
| 84702 | <1% | 15 | $58.74 | |
| 84153 | <1% | 49 | $47.04 | |
| 83540 | <1% | 60 | $41.25 | |
| 0072A | <1% | 46 | $14.30 | |
| 83721 | <1% | 922 | $13.78 | |
| 83550 | <1% | 15 | $10.33 | |
| 84436 | <1% | 651 | $9.03 | |
| 86431 | <1% | 13 | $5.67 | |
| 84479 | <1% | 651 | $3.14 | |
| 91307 | <1% | 135 | $0.03 | |
| 91301 | <1% | 971 | $0.02 | |
| 80050 | General health panel | 0% | 55 | $0.00 |
| 0001A | 0% | 18 | $0.00 | |
| 91300 | 0% | 31 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKINCAID, BRIAN (CEO/OWNER)
Parent organizationETHOS HOLDING CORP
| Provider | Location | Paid |
|---|---|---|
| Naperville Medical Imaging LLC | Naperville, IL | $61K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.